| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gonadotropin-Releasing Hormone | 145 | 2022 | 1205 | 9.430 |
Why?
|
| Hypogonadism | 87 | 2023 | 799 | 6.420 |
Why?
|
| Kallmann Syndrome | 31 | 2022 | 140 | 4.650 |
Why?
|
| Luteinizing Hormone | 99 | 2020 | 869 | 3.590 |
Why?
|
| Follicle Stimulating Hormone | 78 | 2020 | 744 | 3.050 |
Why?
|
| Reproduction | 16 | 2016 | 668 | 2.570 |
Why?
|
| Hypothalamus | 27 | 2017 | 1063 | 2.170 |
Why?
|
| Gonadotropins | 29 | 2010 | 241 | 1.920 |
Why?
|
| Inhibins | 28 | 2013 | 211 | 1.810 |
Why?
|
| Gastrointestinal Hormones | 8 | 2014 | 97 | 1.770 |
Why?
|
| Receptors, Peptide | 9 | 2018 | 272 | 1.480 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 12 | 2017 | 250 | 1.400 |
Why?
|
| Receptors, LHRH | 20 | 2015 | 160 | 1.370 |
Why?
|
| Receptors, G-Protein-Coupled | 17 | 2018 | 1222 | 1.300 |
Why?
|
| Pituitary Gland | 28 | 2013 | 665 | 1.280 |
Why?
|
| Puberty | 15 | 2020 | 490 | 1.210 |
Why?
|
| Neuropeptides | 8 | 2014 | 942 | 1.200 |
Why?
|
| DNA Helicases | 4 | 2017 | 859 | 1.110 |
Why?
|
| Polycystic Ovary Syndrome | 12 | 2012 | 370 | 1.020 |
Why?
|
| Sexual Maturation | 10 | 2020 | 265 | 0.940 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 15 | 1990 | 41 | 0.940 |
Why?
|
| Puberty, Precocious | 16 | 2008 | 156 | 0.910 |
Why?
|
| Extracellular Matrix Proteins | 12 | 2013 | 849 | 0.880 |
Why?
|
| Phenotype | 33 | 2023 | 16365 | 0.870 |
Why?
|
| Endocrine System Diseases | 2 | 2017 | 248 | 0.870 |
Why?
|
| Pedigree | 33 | 2020 | 4644 | 0.820 |
Why?
|
| Testis | 19 | 2013 | 803 | 0.820 |
Why?
|
| Mutation | 45 | 2023 | 29786 | 0.800 |
Why?
|
| Testosterone | 41 | 2020 | 2420 | 0.780 |
Why?
|
| Hypothalamic Diseases | 4 | 2020 | 135 | 0.760 |
Why?
|
| Olfaction Disorders | 8 | 2020 | 222 | 0.730 |
Why?
|
| Neurosecretory Systems | 10 | 2019 | 231 | 0.710 |
Why?
|
| Academic Medical Centers | 9 | 2013 | 2759 | 0.620 |
Why?
|
| Gonadal Steroid Hormones | 13 | 2020 | 712 | 0.620 |
Why?
|
| Estradiol | 27 | 2008 | 2020 | 0.620 |
Why?
|
| DNA-Binding Proteins | 11 | 2017 | 9648 | 0.620 |
Why?
|
| Dwarfism, Pituitary | 1 | 2018 | 46 | 0.610 |
Why?
|
| Neurokinin B | 2 | 2015 | 67 | 0.600 |
Why?
|
| Genitalia | 1 | 2017 | 112 | 0.590 |
Why?
|
| Gonadotrophs | 1 | 2017 | 19 | 0.590 |
Why?
|
| Gonadotropins, Pituitary | 10 | 2001 | 73 | 0.590 |
Why?
|
| Fibroblast Growth Factor 8 | 3 | 2013 | 61 | 0.540 |
Why?
|
| Amenorrhea | 13 | 2012 | 485 | 0.540 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2009 | 780 | 0.540 |
Why?
|
| Mutation, Missense | 7 | 2019 | 2564 | 0.530 |
Why?
|
| Periodicity | 16 | 2011 | 363 | 0.530 |
Why?
|
| Research Support as Topic | 6 | 2004 | 705 | 0.520 |
Why?
|
| Deficiency Diseases | 1 | 2014 | 72 | 0.490 |
Why?
|
| Repressor Proteins | 8 | 2022 | 3023 | 0.480 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1420 | 0.480 |
Why?
|
| Awards and Prizes | 4 | 2014 | 375 | 0.480 |
Why?
|
| Research | 6 | 2007 | 1999 | 0.480 |
Why?
|
| Menstrual Cycle | 15 | 2007 | 551 | 0.460 |
Why?
|
| Endocrinology | 5 | 2014 | 443 | 0.460 |
Why?
|
| Glycoproteins | 11 | 2002 | 2263 | 0.440 |
Why?
|
| Chronobiology Disorders | 1 | 2014 | 74 | 0.440 |
Why?
|
| Hypothalamo-Hypophyseal System | 9 | 2011 | 703 | 0.440 |
Why?
|
| Puberty, Delayed | 7 | 2012 | 115 | 0.440 |
Why?
|
| Receptors, Retinoic Acid | 7 | 2002 | 232 | 0.420 |
Why?
|
| Gonads | 7 | 2020 | 109 | 0.420 |
Why?
|
| Neurons | 12 | 2020 | 9338 | 0.420 |
Why?
|
| Nerve Tissue Proteins | 13 | 2013 | 4462 | 0.420 |
Why?
|
| Fertility | 6 | 2010 | 781 | 0.410 |
Why?
|
| Biomedical Research | 8 | 2013 | 3309 | 0.410 |
Why?
|
| Ovary | 14 | 2011 | 981 | 0.390 |
Why?
|
| Follicular Phase | 11 | 1997 | 153 | 0.380 |
Why?
|
| Seminiferous Tubules | 2 | 2009 | 26 | 0.380 |
Why?
|
| Infertility | 3 | 2010 | 655 | 0.360 |
Why?
|
| Humans | 244 | 2023 | 744343 | 0.360 |
Why?
|
| Radioimmunoassay | 15 | 1995 | 919 | 0.350 |
Why?
|
| DAX-1 Orphan Nuclear Receptor | 8 | 2009 | 29 | 0.350 |
Why?
|
| Ovulation Induction | 8 | 2000 | 274 | 0.350 |
Why?
|
| Zebrafish | 3 | 2022 | 2994 | 0.340 |
Why?
|
| Immunoassay | 3 | 2007 | 752 | 0.340 |
Why?
|
| Luteal Phase | 10 | 1998 | 147 | 0.320 |
Why?
|
| Male | 150 | 2020 | 350118 | 0.320 |
Why?
|
| Genomics | 3 | 2016 | 5720 | 0.310 |
Why?
|
| Models, Organizational | 2 | 2009 | 574 | 0.310 |
Why?
|
| Genetic Association Studies | 6 | 2020 | 2703 | 0.310 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2020 | 2849 | 0.300 |
Why?
|
| Bone Development | 7 | 1991 | 483 | 0.300 |
Why?
|
| Adult | 116 | 2023 | 214055 | 0.290 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 361 | 0.290 |
Why?
|
| Androgens | 11 | 2006 | 1281 | 0.280 |
Why?
|
| CHARGE Syndrome | 2 | 2017 | 31 | 0.280 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 7 | 2000 | 98 | 0.280 |
Why?
|
| Population | 1 | 2006 | 142 | 0.280 |
Why?
|
| Female | 150 | 2023 | 380194 | 0.280 |
Why?
|
| Signal Transduction | 7 | 2020 | 23403 | 0.270 |
Why?
|
| X Chromosome | 7 | 2001 | 814 | 0.270 |
Why?
|
| Progesterone | 15 | 1998 | 776 | 0.260 |
Why?
|
| Receptors, Fibroblast Growth Factor | 2 | 2011 | 185 | 0.260 |
Why?
|
| Genetic Markers | 2 | 2010 | 2634 | 0.260 |
Why?
|
| Aromatase Inhibitors | 5 | 2007 | 491 | 0.260 |
Why?
|
| Metabolism | 1 | 2006 | 196 | 0.260 |
Why?
|
| Animals | 58 | 2023 | 168757 | 0.250 |
Why?
|
| Nose | 2 | 2020 | 509 | 0.250 |
Why?
|
| Infertility, Male | 3 | 2013 | 409 | 0.230 |
Why?
|
| Fibroblast Growth Factors | 3 | 2017 | 879 | 0.230 |
Why?
|
| Pituitary Gland, Anterior | 5 | 1996 | 177 | 0.230 |
Why?
|
| Genetic Variation | 5 | 2016 | 6544 | 0.230 |
Why?
|
| Government Agencies | 1 | 2004 | 156 | 0.230 |
Why?
|
| Polymorphism, Genetic | 4 | 2013 | 4328 | 0.230 |
Why?
|
| Receptors, FSH | 5 | 1998 | 29 | 0.220 |
Why?
|
| Adolescent | 57 | 2020 | 85781 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 1660 | 0.210 |
Why?
|
| Libido | 2 | 2020 | 121 | 0.210 |
Why?
|
| Chorionic Gonadotropin | 4 | 2001 | 477 | 0.210 |
Why?
|
| Ovarian Follicle | 4 | 1999 | 247 | 0.210 |
Why?
|
| Feedback | 11 | 2001 | 795 | 0.200 |
Why?
|
| Private Sector | 2 | 2004 | 392 | 0.200 |
Why?
|
| Protein Precursors | 5 | 2011 | 1154 | 0.200 |
Why?
|
| Spermatogenesis | 5 | 2010 | 262 | 0.200 |
Why?
|
| Adrenal Insufficiency | 2 | 2001 | 184 | 0.200 |
Why?
|
| SOXE Transcription Factors | 1 | 2021 | 57 | 0.190 |
Why?
|
| Base Sequence | 15 | 2014 | 12797 | 0.190 |
Why?
|
| MicroRNAs | 1 | 2017 | 3752 | 0.190 |
Why?
|
| rab3 GTP-Binding Proteins | 1 | 2020 | 29 | 0.190 |
Why?
|
| Amino Acid Substitution | 5 | 2020 | 1791 | 0.190 |
Why?
|
| Developmental Biology | 2 | 2011 | 76 | 0.190 |
Why?
|
| Drug Approval | 1 | 2007 | 742 | 0.180 |
Why?
|
| Receptors, Neurokinin-3 | 2 | 2010 | 54 | 0.180 |
Why?
|
| Molecular Sequence Data | 15 | 2014 | 18111 | 0.180 |
Why?
|
| Spatial Behavior | 1 | 2020 | 90 | 0.180 |
Why?
|
| Follicular Fluid | 4 | 1996 | 87 | 0.180 |
Why?
|
| Body Height | 8 | 2001 | 1577 | 0.180 |
Why?
|
| Genotype | 10 | 2021 | 12951 | 0.170 |
Why?
|
| Activins | 11 | 1998 | 208 | 0.170 |
Why?
|
| Genetic Linkage | 8 | 2003 | 2421 | 0.170 |
Why?
|
| Genetic Techniques | 1 | 2002 | 435 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2020 | 322 | 0.170 |
Why?
|
| Gene Deletion | 4 | 2015 | 2751 | 0.170 |
Why?
|
| Transcription Factors | 11 | 2019 | 12208 | 0.170 |
Why?
|
| Adrenal Glands | 5 | 2001 | 546 | 0.170 |
Why?
|
| Heterozygote | 7 | 2023 | 2804 | 0.170 |
Why?
|
| Steroids | 2 | 2020 | 930 | 0.170 |
Why?
|
| Cooperative Behavior | 4 | 2013 | 1504 | 0.170 |
Why?
|
| Corpus Luteum | 3 | 1996 | 86 | 0.170 |
Why?
|
| Abnormalities, Multiple | 3 | 2020 | 1416 | 0.170 |
Why?
|
| Medical Informatics | 1 | 2005 | 745 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2020 | 462 | 0.160 |
Why?
|
| Body Weight | 4 | 2006 | 4669 | 0.160 |
Why?
|
| Estrogens | 5 | 2000 | 1566 | 0.160 |
Why?
|
| Recombinant Proteins | 13 | 2013 | 6622 | 0.160 |
Why?
|
| DNA Mutational Analysis | 9 | 2020 | 4186 | 0.150 |
Why?
|
| Endocrine System | 1 | 1998 | 113 | 0.150 |
Why?
|
| Reference Values | 13 | 1998 | 4982 | 0.150 |
Why?
|
| Neural Crest | 1 | 2020 | 275 | 0.150 |
Why?
|
| Mice, Knockout | 6 | 2017 | 14557 | 0.150 |
Why?
|
| Hospitals, General | 2 | 2001 | 749 | 0.150 |
Why?
|
| Research Personnel | 3 | 2004 | 573 | 0.150 |
Why?
|
| Ovulation | 9 | 2004 | 189 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 1998 | 277 | 0.150 |
Why?
|
| Choanal Atresia | 1 | 2017 | 39 | 0.150 |
Why?
|
| Computational Biology | 2 | 2013 | 3521 | 0.150 |
Why?
|
| Microphthalmos | 1 | 2017 | 54 | 0.140 |
Why?
|
| Menstruation | 7 | 2011 | 302 | 0.140 |
Why?
|
| Pregnancy, Multiple | 2 | 1994 | 217 | 0.140 |
Why?
|
| Growth Substances | 1 | 1998 | 784 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2007 | 7913 | 0.140 |
Why?
|
| Follistatin | 9 | 1998 | 141 | 0.130 |
Why?
|
| Growth | 2 | 1991 | 376 | 0.130 |
Why?
|
| Receptors, Neuropeptide | 3 | 2005 | 111 | 0.130 |
Why?
|
| Genetic Testing | 4 | 2013 | 3444 | 0.130 |
Why?
|
| Codon, Nonsense | 2 | 2014 | 281 | 0.130 |
Why?
|
| Otolithic Membrane | 1 | 2014 | 38 | 0.130 |
Why?
|
| Haplotypes | 5 | 2015 | 2779 | 0.130 |
Why?
|
| Reproductive Techniques | 1 | 1994 | 42 | 0.120 |
Why?
|
| Mice | 13 | 2023 | 81183 | 0.120 |
Why?
|
| Clinical Medicine | 2 | 2009 | 147 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 1114 | 0.120 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 393 | 0.120 |
Why?
|
| Sperm Count | 4 | 2013 | 216 | 0.120 |
Why?
|
| Leuprolide | 1 | 2016 | 321 | 0.120 |
Why?
|
| Cataract | 1 | 2020 | 834 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 3 | 2013 | 745 | 0.120 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 1005 | 0.120 |
Why?
|
| Endocrine Glands | 3 | 2002 | 103 | 0.120 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.120 |
Why?
|
| Voluntary Programs | 1 | 2013 | 42 | 0.120 |
Why?
|
| Amino Acid Sequence | 9 | 2011 | 13815 | 0.120 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2013 | 13 | 0.120 |
Why?
|
| Genes, Recessive | 4 | 2003 | 641 | 0.110 |
Why?
|
| Anodontia | 1 | 2013 | 49 | 0.110 |
Why?
|
| Time Factors | 20 | 2020 | 40075 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1994 | 224 | 0.110 |
Why?
|
| Synkinesis | 1 | 2013 | 24 | 0.110 |
Why?
|
| Mobius Syndrome | 1 | 2013 | 40 | 0.110 |
Why?
|
| Finger Phalanges | 1 | 2013 | 38 | 0.110 |
Why?
|
| Genetic Load | 1 | 2012 | 15 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2010 | 10943 | 0.110 |
Why?
|
| Pituitary Hormones, Anterior | 3 | 1989 | 65 | 0.110 |
Why?
|
| Cohort Studies | 12 | 2020 | 40561 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 3798 | 0.110 |
Why?
|
| Ovarian Diseases | 2 | 1991 | 139 | 0.110 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2012 | 34 | 0.110 |
Why?
|
| Age of Onset | 3 | 2010 | 3271 | 0.110 |
Why?
|
| Hospital Charges | 1 | 1994 | 362 | 0.110 |
Why?
|
| Organ Size | 3 | 2020 | 2252 | 0.110 |
Why?
|
| Massachusetts | 5 | 2013 | 8663 | 0.100 |
Why?
|
| Syndrome | 3 | 2015 | 3251 | 0.100 |
Why?
|
| Nervous System | 1 | 2015 | 554 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 245 | 0.100 |
Why?
|
| Founder Effect | 1 | 2012 | 189 | 0.100 |
Why?
|
| Peptide Fragments | 4 | 2007 | 5097 | 0.100 |
Why?
|
| HEK293 Cells | 2 | 2018 | 4204 | 0.100 |
Why?
|
| Infusions, Intravenous | 6 | 2007 | 2274 | 0.100 |
Why?
|
| Infusion Pumps | 2 | 1989 | 163 | 0.100 |
Why?
|
| Disorders of Sex Development | 2 | 2006 | 122 | 0.100 |
Why?
|
| Drug Administration Schedule | 8 | 2007 | 4933 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 736 | 0.100 |
Why?
|
| Biological Clocks | 1 | 2014 | 321 | 0.100 |
Why?
|
| Hormones | 5 | 2006 | 889 | 0.100 |
Why?
|
| Age Determination by Skeleton | 3 | 1988 | 129 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2013 | 353 | 0.100 |
Why?
|
| Pituitary-Adrenal System | 2 | 2004 | 553 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 1861 | 0.100 |
Why?
|
| Infertility, Female | 3 | 1999 | 787 | 0.090 |
Why?
|
| Dehydroepiandrosterone Sulfate | 6 | 2004 | 238 | 0.090 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 2 | 2008 | 93 | 0.090 |
Why?
|
| Estrone | 3 | 2007 | 240 | 0.090 |
Why?
|
| Sulfotransferases | 1 | 2011 | 151 | 0.090 |
Why?
|
| Receptors, Tachykinin | 1 | 2010 | 25 | 0.090 |
Why?
|
| Testolactone | 2 | 1991 | 7 | 0.090 |
Why?
|
| Alleles | 3 | 2020 | 6933 | 0.090 |
Why?
|
| Data Collection | 3 | 2013 | 3341 | 0.090 |
Why?
|
| Olfactory Bulb | 1 | 2011 | 200 | 0.090 |
Why?
|
| Tachykinins | 1 | 2010 | 78 | 0.090 |
Why?
|
| Pulsatile Flow | 4 | 2000 | 332 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1655 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1996 | 1203 | 0.090 |
Why?
|
| Middle Aged | 33 | 2020 | 213383 | 0.090 |
Why?
|
| Child | 27 | 2020 | 77709 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 17446 | 0.090 |
Why?
|
| Vomiting | 1 | 2013 | 636 | 0.090 |
Why?
|
| Chromatography, Gel | 3 | 1996 | 668 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 4803 | 0.090 |
Why?
|
| United States | 13 | 2013 | 69872 | 0.090 |
Why?
|
| Cell Movement | 3 | 2011 | 5217 | 0.090 |
Why?
|
| Siblings | 1 | 2014 | 854 | 0.090 |
Why?
|
| Blood Proteins | 1 | 1994 | 1124 | 0.090 |
Why?
|
| Tubulin | 1 | 2013 | 695 | 0.080 |
Why?
|
| Kinetics | 9 | 1994 | 6473 | 0.080 |
Why?
|
| Cryptorchidism | 2 | 2002 | 125 | 0.080 |
Why?
|
| Growth Hormone | 3 | 1989 | 705 | 0.080 |
Why?
|
| Genetic Heterogeneity | 3 | 2008 | 733 | 0.080 |
Why?
|
| Embalming | 1 | 1988 | 13 | 0.080 |
Why?
|
| Osteoporosis | 2 | 1989 | 1580 | 0.080 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 12261 | 0.080 |
Why?
|
| Seminiferous Epithelium | 1 | 2008 | 9 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2020 | 1736 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2011 | 5456 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2017 | 7880 | 0.080 |
Why?
|
| Ketoconazole | 3 | 2007 | 95 | 0.080 |
Why?
|
| Information Systems | 2 | 2008 | 410 | 0.080 |
Why?
|
| Dehydroepiandrosterone | 5 | 1988 | 252 | 0.080 |
Why?
|
| Estriol | 1 | 2007 | 53 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2009 | 220 | 0.080 |
Why?
|
| Physicians | 1 | 2006 | 4567 | 0.080 |
Why?
|
| Blood Specimen Collection | 2 | 1994 | 246 | 0.080 |
Why?
|
| Industry | 2 | 2003 | 365 | 0.080 |
Why?
|
| Ligands | 4 | 2010 | 3282 | 0.080 |
Why?
|
| Phlebotomy | 1 | 2008 | 141 | 0.080 |
Why?
|
| Systems Biology | 1 | 2011 | 469 | 0.080 |
Why?
|
| Gynecomastia | 1 | 1988 | 88 | 0.080 |
Why?
|
| DNA | 8 | 2012 | 7301 | 0.080 |
Why?
|
| Ovarian Neoplasms | 6 | 1998 | 4838 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 3846 | 0.080 |
Why?
|
| Somatomedins | 1 | 1988 | 192 | 0.080 |
Why?
|
| Genetic Counseling | 1 | 2011 | 600 | 0.070 |
Why?
|
| Pulse Therapy, Drug | 2 | 2013 | 35 | 0.070 |
Why?
|
| Societies, Medical | 4 | 2014 | 3743 | 0.070 |
Why?
|
| Estrenes | 1 | 1986 | 23 | 0.070 |
Why?
|
| Abortifacient Agents | 1 | 1986 | 12 | 0.070 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 1986 | 19 | 0.070 |
Why?
|
| Secretory Rate | 3 | 1996 | 82 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2011 | 711 | 0.070 |
Why?
|
| Adolescent Development | 2 | 2020 | 278 | 0.070 |
Why?
|
| Research Subjects | 1 | 2008 | 239 | 0.070 |
Why?
|
| Receptors, Galanin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2011 | 2839 | 0.070 |
Why?
|
| COS Cells | 4 | 2017 | 1161 | 0.070 |
Why?
|
| Pregnancy | 14 | 2006 | 29144 | 0.070 |
Why?
|
| Rats, Inbred Strains | 5 | 1992 | 2186 | 0.070 |
Why?
|
| RNA, Messenger | 9 | 2005 | 13033 | 0.070 |
Why?
|
| Iceland | 1 | 2006 | 183 | 0.070 |
Why?
|
| Case-Control Studies | 6 | 2014 | 21746 | 0.070 |
Why?
|
| Child, Preschool | 17 | 2020 | 41006 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 9959 | 0.070 |
Why?
|
| Epitopes | 3 | 1994 | 2571 | 0.070 |
Why?
|
| Rats | 14 | 1996 | 24260 | 0.070 |
Why?
|
| Osmolar Concentration | 3 | 1995 | 683 | 0.070 |
Why?
|
| Acanthosis Nigricans | 1 | 1985 | 48 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 5 | 1996 | 9274 | 0.070 |
Why?
|
| Models, Animal | 2 | 2010 | 2171 | 0.070 |
Why?
|
| Melatonin | 1 | 1991 | 721 | 0.070 |
Why?
|
| Hirsutism | 1 | 1985 | 69 | 0.070 |
Why?
|
| Olfactory Pathways | 2 | 2020 | 121 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2013 | 765 | 0.070 |
Why?
|
| Nitriles | 2 | 2001 | 956 | 0.070 |
Why?
|
| Adrenal Cortex | 1 | 1986 | 140 | 0.070 |
Why?
|
| Homozygote | 4 | 2010 | 1785 | 0.060 |
Why?
|
| Biological Assay | 5 | 2006 | 652 | 0.060 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 517 | 0.060 |
Why?
|
| Triazoles | 2 | 2001 | 911 | 0.060 |
Why?
|
| Thecoma | 1 | 1984 | 11 | 0.060 |
Why?
|
| Macaca mulatta | 3 | 2007 | 2375 | 0.060 |
Why?
|
| Factor VII | 1 | 2005 | 139 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2008 | 3588 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 2219 | 0.060 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 365 | 0.060 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2004 | 31 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2022 | 581 | 0.060 |
Why?
|
| Multifactorial Inheritance | 1 | 2011 | 1194 | 0.060 |
Why?
|
| Proteins | 3 | 2020 | 6103 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 944 | 0.060 |
Why?
|
| Survivors | 1 | 1994 | 2291 | 0.060 |
Why?
|
| Young Adult | 11 | 2020 | 56430 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 29063 | 0.060 |
Why?
|
| Cross Reactions | 5 | 1996 | 841 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2008 | 587 | 0.060 |
Why?
|
| Safety | 1 | 2008 | 1186 | 0.060 |
Why?
|
| Gene Expression Regulation | 5 | 2007 | 12072 | 0.060 |
Why?
|
| Science | 1 | 2006 | 241 | 0.060 |
Why?
|
| Menorrhagia | 1 | 1983 | 63 | 0.060 |
Why?
|
| Societies | 1 | 2004 | 104 | 0.060 |
Why?
|
| International Cooperation | 1 | 2010 | 1420 | 0.060 |
Why?
|
| Neurogenesis | 2 | 2020 | 838 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2007 | 1202 | 0.060 |
Why?
|
| Career Choice | 1 | 2009 | 744 | 0.050 |
Why?
|
| Injections, Intravenous | 4 | 1990 | 1420 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 1985 | 424 | 0.050 |
Why?
|
| Interinstitutional Relations | 1 | 2004 | 241 | 0.050 |
Why?
|
| Perfusion | 4 | 1995 | 1360 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2915 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1988 | 2015 | 0.050 |
Why?
|
| Injections, Subcutaneous | 5 | 1992 | 666 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18029 | 0.050 |
Why?
|
| Cognition | 1 | 2020 | 6770 | 0.050 |
Why?
|
| Antibody Specificity | 4 | 1996 | 1095 | 0.050 |
Why?
|
| Molecular Weight | 4 | 1996 | 2255 | 0.050 |
Why?
|
| Hemostatics | 1 | 2005 | 229 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2007 | 1526 | 0.050 |
Why?
|
| Contraceptive Agents, Male | 1 | 1981 | 8 | 0.050 |
Why?
|
| Community Networks | 1 | 2004 | 203 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 367 | 0.050 |
Why?
|
| Sensitivity and Specificity | 7 | 2007 | 14722 | 0.050 |
Why?
|
| Diagnosis, Differential | 5 | 1998 | 12959 | 0.050 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2002 | 115 | 0.050 |
Why?
|
| Eunuchism | 1 | 2001 | 19 | 0.050 |
Why?
|
| Testicular Hormones | 1 | 2002 | 188 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2005 | 413 | 0.050 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2023 | 284 | 0.050 |
Why?
|
| Infant | 8 | 2020 | 35136 | 0.050 |
Why?
|
| Boston | 2 | 2006 | 9313 | 0.050 |
Why?
|
| Cleft Palate | 1 | 2006 | 560 | 0.050 |
Why?
|
| Cerebellar Ataxia | 1 | 2002 | 145 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 385 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 152 | 0.050 |
Why?
|
| Insulin | 4 | 2006 | 6580 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2010 | 3494 | 0.050 |
Why?
|
| Physical Examination | 1 | 2006 | 1237 | 0.050 |
Why?
|
| Organizational Case Studies | 1 | 2001 | 299 | 0.050 |
Why?
|
| Symporters | 1 | 2003 | 362 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2000 | 95 | 0.040 |
Why?
|
| Body Mass Index | 3 | 2006 | 12720 | 0.040 |
Why?
|
| Total Quality Management | 1 | 2001 | 274 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 15519 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1471 | 0.040 |
Why?
|
| Family Health | 1 | 2004 | 1282 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2013 | 3209 | 0.040 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2002 | 402 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2014 | 19229 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2022 | 498 | 0.040 |
Why?
|
| CHO Cells | 3 | 2010 | 1406 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2001 | 438 | 0.040 |
Why?
|
| History, 20th Century | 2 | 1997 | 2740 | 0.040 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2000 | 311 | 0.040 |
Why?
|
| Receptors, GABA-A | 1 | 2003 | 627 | 0.040 |
Why?
|
| Space Perception | 1 | 1982 | 475 | 0.040 |
Why?
|
| Bone and Bones | 1 | 1989 | 2575 | 0.040 |
Why?
|
| Hospital Information Systems | 1 | 2001 | 395 | 0.040 |
Why?
|
| Health Services | 1 | 2004 | 758 | 0.040 |
Why?
|
| Haploinsufficiency | 1 | 2020 | 328 | 0.040 |
Why?
|
| Epidemiology | 1 | 2001 | 287 | 0.040 |
Why?
|
| Receptors, Growth Factor | 2 | 1996 | 334 | 0.040 |
Why?
|
| Dipeptides | 1 | 2000 | 409 | 0.040 |
Why?
|
| Leiomyoma | 1 | 1983 | 730 | 0.040 |
Why?
|
| Brain | 3 | 2020 | 26385 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 1994 | 1157 | 0.040 |
Why?
|
| Cricetinae | 3 | 2010 | 2472 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2006 | 4011 | 0.040 |
Why?
|
| Blotting, Western | 5 | 1996 | 5179 | 0.040 |
Why?
|
| Age Factors | 4 | 2020 | 18370 | 0.040 |
Why?
|
| Sleep | 1 | 2014 | 4623 | 0.040 |
Why?
|
| Granulosa Cell Tumor | 1 | 1998 | 71 | 0.040 |
Why?
|
| Reproductive Medicine | 1 | 1999 | 108 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2004 | 1058 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2020 | 880 | 0.040 |
Why?
|
| Dexamethasone | 2 | 2001 | 1951 | 0.040 |
Why?
|
| Inositol Phosphates | 2 | 2010 | 180 | 0.040 |
Why?
|
| Cricetulus | 2 | 2010 | 816 | 0.040 |
Why?
|
| Menopause | 3 | 1992 | 1626 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 15540 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 326 | 0.040 |
Why?
|
| Vinyl Compounds | 1 | 2016 | 20 | 0.040 |
Why?
|
| Teratocarcinoma | 1 | 1996 | 17 | 0.040 |
Why?
|
| Foundations | 1 | 1996 | 94 | 0.040 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1996 | 114 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2004 | 1403 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 150 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 1977 | 330 | 0.030 |
Why?
|
| Estrus | 2 | 1987 | 81 | 0.030 |
Why?
|
| Caenorhabditis elegans | 2 | 2017 | 1419 | 0.030 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 1997 | 105 | 0.030 |
Why?
|
| Nerve Net | 1 | 2008 | 2174 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2010 | 39050 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 1996 | 236 | 0.030 |
Why?
|
| Hypothyroidism | 2 | 1978 | 658 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2004 | 2107 | 0.030 |
Why?
|
| Feedback, Physiological | 2 | 2008 | 479 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1996 | 829 | 0.030 |
Why?
|
| Epithelium | 2 | 2016 | 1679 | 0.030 |
Why?
|
| Triplets | 1 | 1994 | 43 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 4740 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1032 | 0.030 |
Why?
|
| Program Development | 1 | 2001 | 1316 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1977 | 854 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 8863 | 0.030 |
Why?
|
| Peptide Mapping | 1 | 1994 | 263 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 1983 | 1513 | 0.030 |
Why?
|
| Remission, Spontaneous | 2 | 2007 | 382 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1994 | 1801 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 1866 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 2031 | 0.030 |
Why?
|
| Fertilization in Vitro | 2 | 1999 | 1284 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 1941 | 0.030 |
Why?
|
| Smell | 2 | 2009 | 244 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2001 | 648 | 0.030 |
Why?
|
| Disease Progression | 1 | 2010 | 13284 | 0.030 |
Why?
|
| Binding Sites | 3 | 2004 | 6114 | 0.030 |
Why?
|
| Androstenedione | 2 | 2001 | 131 | 0.030 |
Why?
|
| Thyroxine | 1 | 1977 | 667 | 0.030 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 1993 | 53 | 0.030 |
Why?
|
| Sequence Homology | 1 | 2013 | 203 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 1997 | 461 | 0.030 |
Why?
|
| Lod Score | 2 | 2003 | 614 | 0.030 |
Why?
|
| Twins | 1 | 1994 | 339 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2001 | 1181 | 0.030 |
Why?
|
| Thyrotropin | 3 | 1996 | 849 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2013 | 63114 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2001 | 2488 | 0.030 |
Why?
|
| Aged | 8 | 2020 | 163280 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2013 | 274 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1995 | 281 | 0.030 |
Why?
|
| Luciferases | 1 | 1994 | 733 | 0.030 |
Why?
|
| Macromolecular Substances | 3 | 1996 | 1454 | 0.030 |
Why?
|
| Poly A | 1 | 1992 | 185 | 0.030 |
Why?
|
| Antibodies | 2 | 1990 | 2460 | 0.030 |
Why?
|
| Uterus | 3 | 1987 | 711 | 0.020 |
Why?
|
| Priapism | 1 | 1991 | 31 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2020 | 25625 | 0.020 |
Why?
|
| Fetus | 1 | 1998 | 1880 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2029 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 340 | 0.020 |
Why?
|
| Transfection | 2 | 2010 | 5892 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3610 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 1996 | 950 | 0.020 |
Why?
|
| Genes, Helminth | 1 | 2011 | 147 | 0.020 |
Why?
|
| Vagina | 1 | 2016 | 825 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 1991 | 374 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 21827 | 0.020 |
Why?
|
| Mass Screening | 1 | 2006 | 5255 | 0.020 |
Why?
|
| Health Policy | 1 | 2003 | 2661 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2057 | 0.020 |
Why?
|
| Health Personnel | 1 | 2004 | 3218 | 0.020 |
Why?
|
| Azoospermia | 1 | 2010 | 27 | 0.020 |
Why?
|
| Disease Management | 1 | 2001 | 2459 | 0.020 |
Why?
|
| Body Composition | 1 | 1999 | 2401 | 0.020 |
Why?
|
| Glycopeptides | 1 | 1991 | 224 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 2 | 2004 | 58 | 0.020 |
Why?
|
| Body Fluids | 1 | 1991 | 319 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1996 | 2373 | 0.020 |
Why?
|
| Schools, Medical | 1 | 1996 | 880 | 0.020 |
Why?
|
| DNA Primers | 2 | 2009 | 2892 | 0.020 |
Why?
|
| Gene Expression | 4 | 2011 | 7799 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4751 | 0.020 |
Why?
|
| Aging | 3 | 1998 | 8664 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 908 | 0.020 |
Why?
|
| Weight Gain | 1 | 1999 | 2292 | 0.020 |
Why?
|
| Pituitary Neoplasms | 2 | 1989 | 1345 | 0.020 |
Why?
|
| Leydig Cells | 1 | 1988 | 56 | 0.020 |
Why?
|
| Aequorin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cell Division | 4 | 1997 | 4568 | 0.020 |
Why?
|
| Ultrasonography | 3 | 2011 | 5985 | 0.020 |
Why?
|
| Calcifediol | 1 | 1989 | 166 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57776 | 0.020 |
Why?
|
| Chronobiology Phenomena | 1 | 1988 | 30 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Circadian Rhythm | 2 | 1991 | 2624 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2008 | 146 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 1989 | 185 | 0.020 |
Why?
|
| Calcitriol | 1 | 1989 | 298 | 0.020 |
Why?
|
| Injections | 1 | 1991 | 840 | 0.020 |
Why?
|
| Sex Characteristics | 2 | 2010 | 2585 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 625 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 3843 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2008 | 13989 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 8301 | 0.020 |
Why?
|
| Adenoma | 2 | 1989 | 2174 | 0.020 |
Why?
|
| Exons | 2 | 1991 | 2437 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 3870 | 0.020 |
Why?
|
| Forearm | 1 | 1989 | 409 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 2478 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1989 | 426 | 0.020 |
Why?
|
| Activin Receptors | 2 | 1996 | 43 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 517 | 0.020 |
Why?
|
| Hypothalamic Neoplasms | 1 | 1986 | 22 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 865 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 1996 | 19905 | 0.020 |
Why?
|
| Ferritins | 1 | 2008 | 590 | 0.020 |
Why?
|
| Mifepristone | 1 | 1986 | 150 | 0.020 |
Why?
|
| Carcinoma | 1 | 1997 | 2375 | 0.020 |
Why?
|
| Swine | 2 | 1995 | 5917 | 0.020 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 1986 | 98 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 2006 | 231 | 0.020 |
Why?
|
| Prevalence | 1 | 2022 | 15226 | 0.020 |
Why?
|
| Point Mutation | 2 | 2004 | 1623 | 0.020 |
Why?
|
| Receptors, LH | 2 | 1997 | 19 | 0.020 |
Why?
|
| Genes | 1 | 1989 | 1893 | 0.020 |
Why?
|
| Luteinizing Hormone, beta Subunit | 1 | 2004 | 11 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1985 | 380 | 0.020 |
Why?
|
| Models, Biological | 3 | 2008 | 9583 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2011 | 852 | 0.020 |
Why?
|
| Sex | 1 | 1984 | 57 | 0.020 |
Why?
|
| Factor VIIa | 1 | 2005 | 101 | 0.020 |
Why?
|
| Immune Sera | 2 | 1995 | 641 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2004 | 230 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 3 | 1996 | 6314 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1994 | 2795 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 263 | 0.010 |
Why?
|
| Hamartoma | 1 | 1986 | 238 | 0.010 |
Why?
|
| Radius | 1 | 1987 | 422 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 1676 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1991 | 3913 | 0.010 |
Why?
|
| United States Government Agencies | 1 | 2003 | 26 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2012 | 1940 | 0.010 |
Why?
|
| Heart | 1 | 1977 | 4467 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1984 | 2866 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1990 | 1173 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 950 | 0.010 |
Why?
|
| Haplorhini | 1 | 1984 | 552 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1989 | 1801 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1257 | 0.010 |
Why?
|
| Placenta | 2 | 2006 | 1698 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2006 | 959 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 11727 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1983 | 212 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1985 | 1150 | 0.010 |
Why?
|
| Hematocrit | 1 | 1983 | 636 | 0.010 |
Why?
|
| Platelet Count | 1 | 2005 | 781 | 0.010 |
Why?
|
| Progestins | 1 | 1984 | 306 | 0.010 |
Why?
|
| 17-alpha-Hydroxypregnenolone | 1 | 2001 | 5 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6365 | 0.010 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2001 | 22 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1987 | 2008 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 3768 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1992 | 6459 | 0.010 |
Why?
|
| Protein Binding | 1 | 1994 | 9386 | 0.010 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2001 | 55 | 0.010 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1708 | 0.010 |
Why?
|
| Breast | 1 | 2011 | 1969 | 0.010 |
Why?
|
| Cyclic AMP | 2 | 1997 | 1472 | 0.010 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2001 | 98 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 2001 | 108 | 0.010 |
Why?
|
| Investments | 1 | 2003 | 143 | 0.010 |
Why?
|
| Health Occupations | 1 | 2003 | 224 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 15997 | 0.010 |
Why?
|
| Insulin Resistance | 2 | 2004 | 3864 | 0.010 |
Why?
|
| Menstruation-Inducing Agents | 1 | 1980 | 2 | 0.010 |
Why?
|
| Cervix Mucus | 1 | 1980 | 18 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1989 | 1401 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2019 | 77449 | 0.010 |
Why?
|
| Apoptosis | 1 | 1996 | 9727 | 0.010 |
Why?
|
| Douglas' Pouch | 1 | 1979 | 1 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 1988 | 2187 | 0.010 |
Why?
|
| Giant Cell Arteritis | 1 | 2004 | 292 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1999 | 162 | 0.010 |
Why?
|
| Health Priorities | 1 | 2003 | 380 | 0.010 |
Why?
|
| Institutional Practice | 1 | 1999 | 17 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1983 | 607 | 0.010 |
Why?
|
| Spine | 1 | 1987 | 1144 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1985 | 2726 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 11366 | 0.010 |
Why?
|
| Orchiectomy | 1 | 2001 | 474 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2005 | 1189 | 0.010 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 11124 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 1950 | 0.010 |
Why?
|
| Prednisone | 1 | 2004 | 1574 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2008 | 53288 | 0.010 |
Why?
|
| Policy Making | 1 | 2003 | 554 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 2505 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 1534 | 0.010 |
Why?
|
| Confidentiality | 1 | 2003 | 612 | 0.010 |
Why?
|
| Bacteria | 1 | 1989 | 2114 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1996 | 4320 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2005 | 1301 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2266 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2003 | 544 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1991 | 5021 | 0.010 |
Why?
|
| Obesity | 1 | 1999 | 12745 | 0.010 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 1121 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1985 | 1738 | 0.010 |
Why?
|
| Internet | 1 | 2009 | 3064 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1996 | 24 | 0.010 |
Why?
|
| Postmenopause | 2 | 1996 | 2461 | 0.010 |
Why?
|
| Informed Consent | 1 | 2003 | 995 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1996 | 242 | 0.010 |
Why?
|
| Systole | 1 | 1978 | 958 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1997 | 221 | 0.010 |
Why?
|
| Incidence | 1 | 1994 | 20947 | 0.010 |
Why?
|
| Prolactin | 2 | 1989 | 669 | 0.010 |
Why?
|
| Embryo Transfer | 1 | 1999 | 510 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 1998 | 405 | 0.010 |
Why?
|
| Granulosa Cells | 1 | 1996 | 120 | 0.010 |
Why?
|
| Freezing | 1 | 1996 | 303 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 427 | 0.010 |
Why?
|
| Kidney | 1 | 1991 | 7186 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 798 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1996 | 537 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 3748 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 6756 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 2959 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1997 | 506 | 0.010 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 1997 | 450 | 0.010 |
Why?
|
| Calibration | 1 | 1996 | 816 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 3617 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1978 | 1585 | 0.010 |
Why?
|
| Psychometrics | 1 | 1982 | 3002 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1992 | 191 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 13881 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 2400 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1992 | 554 | 0.010 |
Why?
|
| Motivation | 1 | 2001 | 1971 | 0.010 |
Why?
|
| Penile Erection | 1 | 1991 | 97 | 0.010 |
Why?
|
| Calcium | 1 | 1984 | 5756 | 0.010 |
Why?
|
| Cell Separation | 1 | 1996 | 1751 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 4215 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 25043 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 305 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1994 | 1547 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23338 | 0.010 |
Why?
|
| Menarche | 1 | 1992 | 516 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1989 | 570 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1992 | 661 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1989 | 878 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1989 | 803 | 0.010 |
Why?
|
| Introns | 1 | 1991 | 991 | 0.010 |
Why?
|
| DNA Probes | 1 | 1989 | 560 | 0.000 |
Why?
|
| Cattle | 1 | 1994 | 3922 | 0.000 |
Why?
|
| Amino Acids | 1 | 1994 | 1736 | 0.000 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1989 | 460 | 0.000 |
Why?
|
| Bromocriptine | 1 | 1987 | 111 | 0.000 |
Why?
|
| Risk Factors | 1 | 1993 | 72290 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1996 | 5974 | 0.000 |
Why?
|
| Ovarian Cysts | 1 | 1986 | 115 | 0.000 |
Why?
|
| Homeostasis | 1 | 1996 | 3340 | 0.000 |
Why?
|
| Actins | 1 | 1992 | 2121 | 0.000 |
Why?
|
| RNA, Neoplasm | 1 | 1987 | 769 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1987 | 20129 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1991 | 6171 | 0.000 |
Why?
|
| Dopamine | 1 | 1987 | 1591 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1978 | 286 | 0.000 |
Why?
|
| Thyroid Hormones | 1 | 1978 | 390 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 8642 | 0.000 |
Why?
|